BioCentury | Dec 4, 2020
Finance

Dec. 3 Quick Takes: Israeli digital health firm closes $170M fund; plus BioAge, newco Rubedo, Portal Innovations, OliX

...to map age-related molecular pathways, plans to begin clinical trials of HIF-PH inhibitor BGE-117 and PTGDR1...
...Widwin Investment.   TARGETSHIF-PH (EGLN) – Hypoxia-inducible factor prolyl hydroxylasePTGDR1 (DP1) – Prostaglandin D2 receptor subtype DP1 BC...
BioCentury | Oct 13, 2020
Product Development

Gossamer takes a nosedive on Phase II results, but sees path forward in asthma

The failure of Gossamer’s lead program in two Phase II trials continues to sow doubts about the efficacy of drug candidates targeting PTGDR2, but the company believes further analysis of one study’s data still points...
BioCentury | Apr 21, 2020
Product Development

Trio of tactics to target COVID-19 hyperinflammation

Three companies announced COVID-19 programs Monday aimed at blocking the excessive inflammatory response seen in severe cases. Alexion unveiled a global program for its C5 inhibitor Ultomiris, while 4D pharma moved its live biotherapeutic therapy...
BioCentury | Dec 16, 2019
Clinical News

Novartis’ asthma failure weighs on Gossamer’s shares ahead of readout

The latest failure of asthma therapy fevipiprant from Novartis in two Phase III studies dimmed hopes for Gossamer’s lead program, which aims for the same target. Novartis AG (NYSE:NVS; SIX:NOVN) said Monday that pooled results...
BioCentury | Oct 22, 2019
Clinical News

Novartis still bullish on asthma program despite pair of Phase III misses

Novartis is looking ahead to a second set of late-stage readouts next quarter for fevipiprant to treat asthma, despite the candidate’s failure to meet the primary endpoint in two Phase III studies. Along with its...
BioCentury | Sep 6, 2019
Preclinical News

Neon improves predictions for CD4-stimulating tumor antigens

In the latest step toward breaking the barrier to identifying neoantigens displayed on MHCII, Neon has generated a systems biology model that outperforms publicly available predictors. The development brings immuno-oncology closer to personalized therapies directing...
BioCentury | Jun 14, 2019
Product Development

Despite senior management shake-up, Novartis’ pipeline is primed to deliver

A string of departures at Novartis AG and strategic shifts by new CEO Vasant Narasimhan have produced a fairly thorough makeover of the executive committee he inherited in 2018. The team gains a pipeline that...
BioCentury | Apr 9, 2019
Company News

Fosun gains pair of cell therapies from ReNeuron

ReNeuron gained 51p (30%) to 222p on Tuesday after it granted a Fosun subsidiary exclusive rights to develop and commercialize its hRPC and CTX stem cell therapies in China. ReNeuron Group plc (LSE:RENE) will receive...
BioCentury | Feb 13, 2019
Financial News

Gossamer Bio prices $276M IPO

Gossamer Bio Inc. (NASDAQ:GOSS) raised $276 million in an upsized IPO priced late Feb. 7 . Gossamer was up $1.94 (12%) to $17.94 on its first day of trading Feb. 8. Launched officially just 13 months...
BioCentury | Feb 8, 2019
Financial News

Gossamer Bio prices $276M IPO

Gossamer Bio Inc. (NASDAQ:GOSS) raised $276 million in an upsized IPO priced late Thursday. Trading is to begin Friday. Launched officially just 13 months ago by ex-Receptos Inc. executives, Gossamer is developing therapeutics for inflammation,...
Items per page:
1 - 10 of 257